Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 6/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540375 | 0.86 | LTA4H (0.52) | SLC1A3SLC1A1ALDH1A1LTA4HSLC15A1 | |
| SCHEMBL31668437 | 0.85 | LTA4H (0.44) | SLC1A3SLC1A1ALDH1A1LTA4HSLC15A1 | |
| SCHEMBL20880748 | 0.85 | ALDH1A1 (0.44) | SLC1A3SLC1A1ALDH1A1LTA4HSLC15A1 | |
| SCHEMBL23937606 | 0.85 | ALDH1A1 (0.44) | SLC1A3SLC1A1ALDH1A1LTA4HSLC15A1 | |
| SCHEMBL23937492 | 0.85 | ALDH1A1 (0.44) | SLC1A3SLC1A1ALDH1A1LTA4HSLC15A1 | |
| SCHEMBL26940361 | 0.83 | TGM2 (0.44) | SLC1A3SLC1A1ALDH1A1LTA4HHCAR2 | |
| SCHEMBL30415091 | 0.81 | ALDH1A1 (0.46) | SLC1A3SLC1A1ALDH1A1LTA4HHCAR2 | |
| SCHEMBL30297646 | 0.80 | ALDH1A1 (0.45) | SLC1A3SLC1A1ALDH1A1SLC15A1MAPK1 | |
| SCHEMBL29825801 | 0.78 | ALDH1A1 (0.49) | SLC1A3SLC1A1ALDH1A1LTA4HHCAR2 | |
| SCHEMBL29403049 | 0.78 | SLC7A5 (0.58) | SLC1A3SLC1A1ALDH1A1LTA4HSLC15A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | SLC1A3 11/4885SLC1A1 15/4885ALDH1A1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.